Janux Therapeutics Inc share price logo

Janux Therapeutics Inc Share Price

NASDAQ: JANX

Small Cap

$15.23

+0.33

(+2.21%)

as on

Janux Therapeutics Inc Stock Performance

as on April 15, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $14.94
    $15.50
    downward going graph

    1.90%

    Downside

    1.77%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $12.12
    $35.34
    downward going graph

    20.42%

    Downside

    132.04%

    Upside

    downward going graph

Janux Therapeutics Inc share price movements today

Previous Close
$14.90
Open
$14.94
Volume
663.3K
Day's Low - High
$14.94 - $15.50
52 Week Low - High
$12.12 - $35.34

Janux Therapeutics Inc Historical Returns

1 Month Return
+ 9.72 %
3 Month Return
+ 5.52 %
1 Year Return
-48.53 %
3 Year Return
+ 1.78 %
5 Year Return
0 %

Janux Therapeutics Inc Stock Fundamentals & Key Indicators

Check Janux Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$908.2M

EPS (TTM)

-2.5186

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-155.6M

Revenue (TTM)

10.0M

Profit Margin

0.00%

Return On Equity TTM

-11.48%

Janux Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Janux Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Janux Therapeutics Inc image
Janux Therapeutics Inc
BUY$908.2MNANA0.00%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$42.7B140.76%138.848.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$111.0B102.67%28.532.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$35.6BNA124.865.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$79.2B55.14%18.0531.41%

Stock Returns calculator for Janux Therapeutics Inc Stock including INR - Dollar returns

The Janux Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Janux Therapeutics Inc investment value today

Current value as on today

₹56,908

Returns

-₹43,092

(-43.09%)

Returns from Janux Therapeutics Inc Stock

-₹47,392 (-47.39%)

Dollar Impact

₹4,300 (+4.3%)

Analyst Recommendation on Janux Therapeutics Inc Stock

Based on 15 analysts

BUY

93.33%

Buy

6.67%

Hold

0.00%

Sell

Based on 15 analysts, 93.33% of analysts recommend a 'BUY' rating for Janux Therapeutics Inc. Average target price of $54

Janux Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Janux Therapeutics Inc.

What analysts predicted

71.8%UPSIDE

Target Price

$54

Current Price

$15.23

Analyzed by

15 Analysts

Target

$54.00

Janux Therapeutics Inc target price $54, a slight upside of 71.8% compared to current price of $15.23. According to 15 analysts rating.

Janux Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Janux Therapeutics Inc Stock has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-33% versus previous 30 day period

Janux Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
2
2
1
8
0
-8
-
-
10
7
Gross Profit
2
1
0
8
0
-9
0
0
9
-1
Operating Income
-15
-16
-20
-13
-35
-29
-34
-45
-35
-42
EBITDA
-15
-15
-19
-13
-35
-28
-34
-44
-23
-31
Interest Expense
-
3
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-11
-11
-14
-5
-28
-20
-23
-33
-24
-31
Income Tax Expense
0
0
0
-
-
-
-
-
-
-
Net Income
-11
-11
-14
-5
-28
-20
-23
-33
-24
-31
Net Profit Margin
-459.59%
-477.77%
-1178.91%
-66.98%
-6391.57%
237.50%
0.00%
0.00%
-243.13%
-405.41%

Janux Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
0
3
8
8
10
10
Gross Profit
0
0
3
8
6
8
7
Operating Income
-3
-4
-32
-67
-72
-98
-157
EBITDA
-3
-6
-32
-66
-71
-96
-111
Interest Expense
0
0
0
4
-
-
-
Depreciation
0
0
0
0
1
2
2
Income Before Tax
-4
-6
-32
-63
-58
-68
-113
Income Tax Expense
0
-1
0
-8
1
-
-
Net Income
-4
-6
-32
-54
-58
-68
-113
Net Profit Margin
0.00%
-1785.26%
-895.22%
-628.82%
-721.18%
-651.62%
-1136.25%

Janux Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-11
-14
-5
-28
-20
-23
-33
-24
81
Operating Cash Flow
-9
-14
-10
-2
-16
-17
-23
-12
-28
Investing Cash Flow
11
-113
-190
12
33
-340
1
8
29
Financing Cash Flow
0
322
2
1
386
0
0
0
2
Change in Cash
2
193
-198
12
403
-356
-21
-4
3

Janux Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-6
-32
-63
-58
-68
-113
Operating Cash Flow
-4
-16
-42
-50
-43
-82
Investing Cash Flow
-340
-340
58
-41
-258
-300
Financing Cash Flow
11
386
0
59
713
4
Change in Cash
7
28
15
-32
411
-378

Global Institutional Holdings in Janux Therapeutics Inc

Funds
Holdings
FMR Inc
5.77%
Balyasny Asset Management LLC
1.46%
Orbimed Advisors, LLC
2.9%
State Street Corp
3.11%
TCG Crossover Management, LLC
2.94%
See all

Janux Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 02 December

    Tue, 10:03 PM

    -

    Janux Therapeutics stock fell 47% after disappointing early-stage prostate cancer trial data.

Insights on Janux Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 38.7% return, outperforming this stock by 87.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 63.3% return, outperforming this stock by 61.5%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 10.0M → 7.88M (in $), with an average decrease of 21.2% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -24.31M → -31.94M (in $), with an average decrease of 31.4% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 6 months, JANX stock has moved down by -42.1%

About Janux Therapeutics Inc

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
OrganisationJanux Therapeutics Inc
Headquarters10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130
IndustryBiotechnology
CEODr. David Alan Campbell Ph.D.
E-voting on sharesClick here to vote

Key Management of Janux Therapeutics Inc

Name

Title

Ms. Maria Dobek

Vice President of Accounting

Mr. Charles M. Winter

Chief Technical Officer

Mr. James Pennington

General Counsel & Corporate Secretary

Ms. Janeen Doyle

Chief Corporate & Business Development Officer

Dr. William Y. Go M.D., Ph.D.

Chief Medical Officer

Dr. David Alan Campbell Ph.D.

President, CEO & Director

Dr. Thomas Diraimondo Ph.D.

Chief Scientific Officer

Mr. Matt Whitmire

Vice President of Finance

FAQs

What is Janux Therapeutics Inc share price today?

Janux Therapeutics Inc share price today is $15.23 as on at the close of the market. Janux Therapeutics Inc share today touched a day high of $15.5 and a low of $14.94.

What is the 52 week high and 52 week low for Janux Therapeutics Inc share?

Janux Therapeutics Inc share touched a 52 week high of $35.34 on and a 52 week low of $12.12 on . Janux Therapeutics Inc stock price today i.e. is closed at $15.23,which is 56.90% down from its 52 week high and 25.66% up from its 52 week low.

What is Janux Therapeutics Inc's market capitalisation today?

Janux Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Janux Therapeutics Inc Stock (JANX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Janux Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Janux Therapeutics Inc Shares that will get you 0.0985 shares as per Janux Therapeutics Inc share price of $15.23 per share as on April 15, 2026 at 1:29 am IST.

What is the minimum amount required to buy Janux Therapeutics Inc Stock (JANX) from India?

Indian investors can start investing in Janux Therapeutics Inc (JANX) shares with as little as ₹93.082 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹930.82 in Janux Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Janux Therapeutics Inc share’s latest price of $15.23 as on April 15, 2026 at 1:29 am IST, you will get 0.6566 shares of Janux Therapeutics Inc. Learn more about fractional shares .